ReviewNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2017
Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise.
Review in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Biologicals for the treatment of lupus nephritis: a Bayesian network meta-regression analysis.Frontiers in immunology · 2024Pooled it
- Diagnostic value of TWEAK for predicting active lupus nephritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis.Renal failure · 2021Pooled it
- Macrophage pyroptosis in lupus nephritis - Novel insights into renal pathogenesis and clinical correlates: A cross-sectional study.Medicine · 2026Observational
- Defining PI3K Signaling as a Key Regulator of Molecular Heterogeneity and Inflammation in Glomerular Lupus Nephritis.Immune network · 2026Article
- Urinary ALCAM signatures define renal activity and therapeutic response in juvenile lupus nephritis.Pediatric rheumatology online journal · 2026Article
- Clinical Predictors of Underlying Histologic Activity in Patients with Lupus Nephritis: A Focus on Urinary Soluble CD163.Journal of clinical medicine · 2025Article
- Observational
- Clinical Relevance of Anti-C3 and Anti-C4 Autoantibodies in Lupus Nephritis.Kidney international reports · 2024Article
- Machine learning-based identification of novel hub genes associated with oxidative stress in lupus nephritis: implications for diagnosis and therapeutic targets.Lupus science & medicine · 2024Article
- Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis.JCI insight · 2024Article
- Article
- Alternative pathway diagnostics.Immunological reviews · 2023Review
- A Histology-Guided Approach to the Management of Patients with Lupus Nephritis: Are We There Yet?Biomedicines · 2022Review
- Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis.Arthritis & rheumatology (Hoboken, N.J.) · 2022Article
- Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria.Lupus science & medicine · 2022Review
- Prediction models of treatment response in lupus nephritis.Kidney international · 2022Article
- Adhesion molecules: a way to understand lupus.Reumatologia · 2022Review
- The Association of Complements, TGF-International journal of inflammation · 2022Article
- Urinary soluble alpha chain of the interleukin-2 receptor as a biomarker of active lupus nephritis in Egyptian children with juvenile systemic lupus erythematosus.Archives of rheumatology · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Biomarker development in lupus nephritis (LN) has traditionally relied on comparing the characteristics of candidate markers to clinical findings in patients and controls from cross-sectional cohorts. In this work, two additional strategies for LN biomarker development that are gaining ground will be discussed. One approach compares analytes directly to kidney histology. The second strategy utilizes longitudinal measurements of biomarker levels at regular intervals as patients move from disease quiescence to disease flare. These approaches have begun to empower biomarkers as diagnostic and prognostic tools in LN and have revealed novel and sometimes unexpected roles for these biomarkers in the pathogenesis and prediction of LN disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.